| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-06 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.12 | 4e-05 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |